Scilex (NASDAQ:SCLX - Get Free Report)'s stock had its "buy" rating reiterated by stock analysts at D. Boral Capital in a report released on Friday,Benzinga reports. They presently have a $22.00 target price on the stock.
Scilex Price Performance
SCLX stock traded up $0.01 during trading on Friday, hitting $0.30. The stock had a trading volume of 1,936,917 shares, compared to its average volume of 1,402,532. The company's 50-day moving average price is $0.40 and its two-hundred day moving average price is $0.70. Scilex has a twelve month low of $0.21 and a twelve month high of $2.30. The stock has a market capitalization of $73.16 million, a P/E ratio of -0.36 and a beta of 1.06.
Scilex (NASDAQ:SCLX - Get Free Report) last issued its quarterly earnings results on Friday, January 17th. The company reported ($0.18) earnings per share (EPS) for the quarter. As a group, sell-side analysts expect that Scilex will post -0.57 EPS for the current fiscal year.
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently made changes to their positions in the stock. Janus Henderson Group PLC increased its holdings in shares of Scilex by 28.7% in the fourth quarter. Janus Henderson Group PLC now owns 687,547 shares of the company's stock valued at $293,000 after purchasing an additional 153,245 shares during the last quarter. RA Capital Management L.P. boosted its position in shares of Scilex by 296.7% during the 4th quarter. RA Capital Management L.P. now owns 1,036,218 shares of the company's stock valued at $442,000 after acquiring an additional 775,039 shares during the last quarter. Jane Street Group LLC boosted its position in shares of Scilex by 965.8% during the 4th quarter. Jane Street Group LLC now owns 321,480 shares of the company's stock valued at $137,000 after acquiring an additional 291,316 shares during the last quarter. Northern Trust Corp grew its holdings in shares of Scilex by 64.0% in the fourth quarter. Northern Trust Corp now owns 1,273,968 shares of the company's stock valued at $543,000 after purchasing an additional 497,182 shares during the period. Finally, Norges Bank acquired a new stake in Scilex during the fourth quarter worth about $204,000. 69.67% of the stock is currently owned by institutional investors and hedge funds.
Scilex Company Profile
(
Get Free Report)
Scilex Holding Company focuses on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Its commercial products include ZTlido (lidocaine topical system) 1.8% (ZTlido), a prescription lidocaine topical product for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a ready-to-use oral solution for the acute treatment of migraine with or without aura in adults; and GLOPERBA, a liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults.
Read More
Before you consider Scilex, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Scilex wasn't on the list.
While Scilex currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
